|
Accueil > Actualité
Merck: FDA grants priority review to Keytruda
(CercleFinance.com) - Merck said its blockbuster drug Keytruda has been granted a priority review status by the US Food and Drug Administration, accelerating its regulatory process.
The FDA has accepted priority review for a new supplemental application for Merck's antitherapy seeking approval for the treatment of patients with high-risk, non-muscle invasive bladder cancer. Merck targets an action date in January 2020. Copyright (c) 2019 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
